2022
DOI: 10.1016/j.sopen.2022.04.004
|View full text |Cite
|
Sign up to set email alerts
|

A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 38 publications
0
6
0
Order By: Relevance
“…Previously, our group demonstrated the feasibility of using the 5×-multiplier in a cohort of patients undergoing liver or pancreas resections . We then expanded the 5×-multiplier to the entire department of surgical oncology in a follow-up prospective study that showed feasibility in multiple types of cancer surgery, regardless of LOS . We demonstrated a progressive, sustained decline in discharge opioid prescriptions that coincided with increasing compliance (89.2% in V3) with the 5×-multiplier guideline, with no reflexive increased refill needs.…”
Section: Discussionmentioning
confidence: 92%
See 1 more Smart Citation
“…Previously, our group demonstrated the feasibility of using the 5×-multiplier in a cohort of patients undergoing liver or pancreas resections . We then expanded the 5×-multiplier to the entire department of surgical oncology in a follow-up prospective study that showed feasibility in multiple types of cancer surgery, regardless of LOS . We demonstrated a progressive, sustained decline in discharge opioid prescriptions that coincided with increasing compliance (89.2% in V3) with the 5×-multiplier guideline, with no reflexive increased refill needs.…”
Section: Discussionmentioning
confidence: 92%
“…The second cohort (V2: February 1, 2019, to October 31, 2020; n = 229) updated patient and surgeon education handouts, standardized intravenous patient-controlled anesthesia (IV-PCA) dosage, suggested (not mandatory) a 3-drug (acetaminophen, celecoxib, methocarbamol) nonopioid bundle starting on postoperative days (PODs) 0 to 1, and implemented the 5×-multiplier (last 24-hour OME multiplied by 5) to calculate discharge volume . Medications were converted to oral formulations per surgeon perception of tolerance.…”
Section: Methodsmentioning
confidence: 99%
“…We found that robotic PD was associated with decreased inpatient opioid use with similar postoperative pain scores. In both robotic PD and open PD groups, we found relatively low opioid usage due to several iterative changes we have made across our Department of Surgical Oncology for postoperative analgesia across disease sites 5,13,14,18–26 . Lower inpatient opioid use then led to reduced discharge prescription volumes overall.…”
Section: Discussionmentioning
confidence: 93%
“…In both robotic PD and open PD groups, we found relatively low opioid usage due to several iterative changes we have made across our Department of Surgical Oncology for postoperative analgesia across disease sites. 5,13,14,[18][19][20][21][22][23][24][25][26] Lower inpatient opioid use then led to reduced discharge prescription volumes overall. On multivariate analysis, the robotic approach, absence of a pancreatic fistula and older age were associated with decreased OME.…”
Section: Discussionmentioning
confidence: 99%
“…A rational way to determine a reasonable amount of opioid pills is to use a multiplier. 28,29 If you look at the patient's use of opioid pills over the 48 hours before discharge, you can estimate the average daily number of pills a patient might require after discharge. No evidence-based multiplier exists for the trauma population, but at our center, we provide a week's worth of opioid pills, meaning a multiplier of 7.…”
Section: Opioid Prescribing At Dischargementioning
confidence: 99%